LifeVantage Corporation reported its financial results for the second quarter of fiscal 2026, ending December 31, 2025, showing a decline in revenue compared with the prior year period, according to the company. For the quarter, revenue was $48.9 million, a 27.8 percent decrease from the $67.8 million reported in the second quarter of fiscal 2025, though sequentially revenue increased 2.9 percent from the first quarter of fiscal 2026. The decline was driven mainly by lower sales of the MindBody GLP-1 System, partially offset by contributions from the LoveBiome product line acquired in October 2025.
Gross profit for the quarter was $36.2 million, representing 74.0 percent of revenue, down from 80.5 percent in the prior year period, reflecting a $2.4 million allowance for inventory obsolescence and increased distribution costs, the company said that. Adjusted non-GAAP results showed operating income of $2.6 million and adjusted net income of $1.9 million, or $0.15 per diluted share, compared with $3.9 million and $3.0 million, or $0.22 per diluted share, a year earlier. Net income on a GAAP basis was $0.3 million, or $0.02 per diluted share. Adjusted EBITDA was $3.9 million versus $6.5 million in the comparable quarter of fiscal 2025.
On the balance sheet, LifeVantage reported $10.2 million in cash and cash equivalents and no outstanding debt at December 31, 2025, while generating $0.5 million of cash from operations in the first six months of fiscal 2026, the company said that. The Board of Directors approved a new $60 million share repurchase program through December 31, 2027, and declared a quarterly cash dividend of $0.045 per common share, payable March 16, 2026 to stockholders of record on March 2, 2026. LifeVantage also provided full-year fiscal 2026 guidance, expecting revenue of $185 million to $200 million, adjusted EBITDA of $15 million to $19 million, and adjusted earnings per share of $0.60 to $0.80.
